In Black men, the number of repeats in a specific gene doesn’t seem to affect whether they get prostate cancer — even if the number is short or long, their risk stays about the same.
Scientific Claim
Androgen receptor gene CAG repeat length is not associated with prostate cancer risk in African-American men after adjusting for age, with an odds ratio of 1.05 per repeat (95% CI, 0.98–1.13; P = 0.16), suggesting that variation in this genetic marker does not meaningfully influence prostate cancer likelihood in this population.
Original Statement
“After adjusting for age, we found no association between prostate cancer risk and CAG repeat length (odds ratio, 1.05; 95% CI, 0.98-1.13; P = 0.16).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study is a case-control design, which can only assess association, not causation. The authors correctly used 'no association' and reported an odds ratio with confidence interval, using appropriate statistical language.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether the lack of association between CAG repeat length and prostate cancer risk in African-American men holds across multiple high-quality case-control and cohort studies.
Whether the lack of association between CAG repeat length and prostate cancer risk in African-American men holds across multiple high-quality case-control and cohort studies.
What This Would Prove
Whether the lack of association between CAG repeat length and prostate cancer risk in African-American men holds across multiple high-quality case-control and cohort studies.
Ideal Study Design
A systematic review and meta-analysis of 15+ large, population-based case-control or cohort studies of African-American men, all using standardized PCR methods to measure CAG repeats, adjusting for age, family history, and PSA screening status, with prostate cancer diagnosis confirmed by biopsy, and pooling individual-level data to calculate pooled ORs with subgroup analysis by age and tumor stage.
Limitation: Cannot establish causation or rule out unmeasured confounding across studies.
Prospective Cohort StudyLevel 2bWhether CAG repeat length measured at baseline prospectively predicts future prostate cancer diagnosis in African-American men.
Whether CAG repeat length measured at baseline prospectively predicts future prostate cancer diagnosis in African-American men.
What This Would Prove
Whether CAG repeat length measured at baseline prospectively predicts future prostate cancer diagnosis in African-American men.
Ideal Study Design
A prospective cohort of 5,000 African-American men aged 45–65, with baseline CAG repeat length measured via PCR, followed for 10+ years with annual PSA testing and biopsy for suspected cancer, adjusting for age, BMI, family history, and socioeconomic factors, with primary outcome: incident prostate cancer.
Limitation: Cannot prove biological mechanism; may be affected by loss to follow-up or screening bias.
Case-Control StudyLevel 3bIn EvidenceWhether CAG repeat length differs between men with and without prostate cancer in a well-matched African-American population.
Whether CAG repeat length differs between men with and without prostate cancer in a well-matched African-American population.
What This Would Prove
Whether CAG repeat length differs between men with and without prostate cancer in a well-matched African-American population.
Ideal Study Design
A case-control study of 1,000 African-American men with biopsy-proven prostate cancer and 1,000 age-, race-, and PSA-screening-matched controls, with CAG repeats measured blinded to diagnosis, using the same lab protocol, and adjusting for potential confounders via multivariable regression.
Limitation: Prone to recall and selection bias; cannot determine temporal sequence.
Evidence from Studies
Supporting (1)
Scientists looked at a specific gene part in Black men and found that whether it was longer or shorter didn’t really change their chance of getting prostate cancer after accounting for age — so the gene variation doesn’t seem to matter much for risk.